Clinical trials: Helicobacter
H. Pylori Infection
H. Pylori Treatment Between Modified Quadruple Regimen and Tailored Therapy
The rate of H. pylori resistance to antimicrobial agents including clarithromycin (CAM) has increased worldwide. Eradication failure using triple therapy is strongly associated with CAM-resistant H. pylori.
- Trial name
- NCT05002595
- Testing
- H. pylori eradication
- Where
- South Korea
- Volunteers
- 270 people
- Sponsor
- Soonchunhyang University Hospital
HELICOBACTER PYLORI INFECTIONS
Real-World Study of Helicobacter Pylori Eradication Success and Its Determinants
This study aims to evaluate the real-world effectiveness of different treatment regimens used to eradicate Helicobacter pylori (H. pylori) infection in routine clinical practice. H.
- Trial name
- NCT07374822
- Testing
- No Study-Assigned Intervention
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Run-hua Li
Describe Current Practices in Hpylori Diagnosis
Assessing Knowledge, Practices, Attitudes and Barriers of Puplic Population Regarding Helicobacter Pylori Infection in Upper Egypt: Cross- Sectional Study
Assess non medical population knowledge of H. pylori epidemiology, diagnostic methods, treatment guidelines, and complications. Evaluate attitudes toward the importance of testing, eradication, and antibiotic resistance concerns.
- Trial name
- Hpylori/KAP (NCT07043881)
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Assiut University
Cure Rate of Helicobacter Pylori Infection
Levofloxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection
To test the efficacy of 14 day levofloxacin and bismuth-containing second-line therapy for resistant Helicobacter pylori infection, to compare with the classical quadruple therapy.
- Trial name
- NCT01742429
- Testing
- Proton pump inhibitor, Bismuth subsalicylate, Metronidazole
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Gastric (Stomach) Cancer
Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial
This study is a prospective, multicenter cluster randomized controlled trial. Additional fecal screening for high-risk SNP subtypes, in conjunction with routine Hp testing, may improve the identification of individuals at high…
- Trial name
- NCT06943794
- Testing
- recommendations for Hp eradication treatment
- Where
- China
- Volunteers
- 4,824 people, healthy volunteers welcome
- Sponsor
- Fudan University
Peptic Ulcer, Helicobacter Pylori Infection
The Prevalence of Helicobacter Pylori in Shanghai, 2013 to 2019
The study was a cross-sectional single-center study, conducted at Renji Hospital, Shanghai Jiaotong university school of medicine.
- Trial name
- NCT04636866
- Testing
- NO intervention
- Where
- China
- Volunteers
- 400,000 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Helicobacter Pylori
A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication
We aim to assess and compare the effectiveness of clarithromycin- and furazolidone-based regimens as primary therapies in eradicating H. pylori.
- Trial name
- NCT03716622
- Testing
- Furazolidone, Clarithromycin
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Shandong University
Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
RCT: Triple vs Sequential vs Concomitant Therapy H Pylori
Triple therapy (TT) comprising proton pump inhibitor (PPI), amoxicillin 1g and clarithromycin 500mg twice daily has long been considered one of the standard treatment for H.
- Trial name
- NCT02092506
- Testing
- 10 day triple therapy, 10 day sequential therapy, 10 day concomitant therapy
- Where
- Singapore
- Volunteers
- 462 people
- Sponsor
- Changi General Hospital
Helicobacter Pylori Infection
Efficacy and Safety of an H.Pylori Vaccine in H.Pylori-Negative Adults
To study the safety, immunogenicity and efficacy of an investigational H. pylori vaccine, compared with placebo.
- Trial name
- NCT00736476
- Testing
- H.pylori vaccines
- Where
- Germany
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Helicobacter Pylori Infection
Effectiveness of Once-daily Dose Regimen of 7-day and 14-day High Dose Rabeprazole-levofloxacin Based Quadruple Therapy for H. Pylori Eradication in Thai Patients With Non-ulcer Dyspepsia
H.pylori is an organism which causes gastric inflammation, peptic ulcer disease (PUD), mucosa associated lymphoid tissue (MALT) lymphoma and gastric cancer.
- Trial name
- NCT03397680
- Testing
- 13C Urea Breath Test
- Where
- Thailand
- Volunteers
- 100 people
- Sponsor
- Thammasat University
Helicobacter Pylori Infection
Efficacy and Safety of Lacidofil® STRONG as an Adjuvant for Helicobacter Pylori Treatment in Non-ulcer Dyspepsia
Treatment for H. pylori eradication includes antibiotics. The treatment has decreased its efficiency (lower capability to eradicate the infection) due to increasing antibiotic resistance in the population.
- Trial name
- NCT04473079
- Testing
- Lacidofil
- Where
- Thailand
- Volunteers
- 90 people
- Sponsor
- Lallemand Health Solutions
Helicobacter Pylori Infection, Gastritis
Comparison Between High-dose Amoxicillin Dual Therapy and Pylera Quadruple Therapy in the Treatment of Helicobacter Pylori Infection
Helicobacter pylori is a pathogenic bacteria transmitted from individual to individual, being scientifically recognized as an agent who causes persistent inflammatory activity on the gastric mucosa.
- Conditions
- Helicobacter Pylori Infection, Gastritis, Gastric Cancer
- Trial name
- NCT05100446
- Testing
- Amoxicillin - high dose dual therapy, Pylera, Esomeprazole 40mg
- Where
- Portugal
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Unidade Local de Saúde do Alto Ave, EPE
Peptic Ulcer, Dyspepsia
HEP-FYN 12-Years Follow-up
Aims: 1. Evaluate the long-term effect of screening and eradication of Helicobacter Pylori on the prevalence of dyspepsia, and, as secondary outcomes, to assess the effect on dyspepsia related health-care consumption and quality…
- Conditions
- Peptic Ulcer, Dyspepsia, Reflux
- Trial name
- NCT02001727
- Testing
- 13C-Urea breath test for Helicobacter Pylori, Questionaire
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Gastroesophageal Reflux Disease (GERD)
Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients
The primary objective of this study is to investigate whether eradication treatment of Helicobacter pylori followed by therapy with esomeprazole for a total of 8 weeks extends the time to relapse in patients with gastroesophageal…
- Trial name
- NCT00574925
- Testing
- Esomeprazole
- Where
- Switzerland
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Zurich
Functional Dyspepsia, Peptic Ulcer
Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment
To examine and compare the efficacy of 2 week Levofloxacin-containing therapies with and without Bismuth for H.pylori treatment.
- Trial name
- NCT01667718
- Testing
- Bismuth, Lansoprazole, Levofloxacin
- Where
- China
- Volunteers
- 161 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Helicobacter Pylori Infection
Study the Effect of Probiotics Combined With Bismuth Quadruple Rescue Therapy on H Pylori Infective Patients
Retrospectivly follow-up the outpatients for H pylori eradication failures more than 2 times in the digestive department of Changhai hospital from 2015-2017,analyse the eradication rates and adverse effects of the therapy with…
- Trial name
- NCT03297242
- Volunteers
- 30 people
- Sponsor
- Changhai Hospital
Helicobacter Pylori Infection
Comparison of Two Novel First-line Anti-Helicobacter Pylori Therapy
The Asian-Pacific Consensus Report has recommended that proton pump inhibitor (PPI)-clarithromycin-amoxicillin or metronidazole treatment for 7 to14 days is the first choice treatment for H pylori infection.
- Trial name
- NCT03383003
- Testing
- Nexium, Amolin, Klaricid
- Where
- Taiwan
- Volunteers
- 240 people
- Sponsor
- Chang Gung Memorial Hospital
Gastroesophageal Reflux Disease
Symptom Assessment for GERD Patients Receiving H. Pylori Eradication
Background: Rebound acid hypersecretion and acid-related symptoms after discontinuation of proton-pump inhibitor has been reported in previous studies.
- Trial name
- NCT01249482
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- National Taiwan University Hospital
Helicobacter Pylori
Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management
The study will evaluate the eradication rate and tolerability of modified LOAD regimens (three antibiotics and a proton pump inhibitor (lansoprazole)) for management of HP infection in treatment-naive patients as well as patients…
- Trial name
- NILE (NCT05184491)
- Testing
- Naïve patients - ACO therapy, Naïve patients - LNDL therapy, Naïve patients - MNDL therapy
- Where
- Egypt
- Volunteers
- 500 people
- Sponsor
- National Liver Institute, Egypt
Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy
Compare efficacy and safety of 10-day triple therapy (rabeprazole, clarithromycin and amoxicillin) plus N-acetylcystein versus 10-day concomitant therapy (rabeprazole, clarithromycin, amoxicillin and metronidazole) for…
- Trial name
- NCT01572597
- Testing
- 10RAC+acetylcystein, 10RAC+metronidazole
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Buddhist Tzu Chi General Hospital